Proteome Systems [ASX: PXL] has stopped development of a prostate cancer diagnostics test, after concluding that bringing the product to market would take too long.

Proteome had discovered cancerous prostate tissues demonstrate increased expression of Human Carcinoma Antigen [HCA], and developed an assay for detection of HCA in semen samples.

But the company concluded that developing the assay for commercialisation would take too long and consume too many resources.

A spokesperson for the company said Proteome was committed to projects with near-term revenue potential.